Skip to main content

Advertisement

SpringerLink
Log in

Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A Correction to this article was published on 08 November 2016

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 13 September 2016

    In the version of this article initially published, on page 676, the top of column 3, the article states that Wave Life Sciences hopes to file its first two IND filings this year; it should have said that the application in Huntington's will be filed this year and the one for DMD in 2017. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance. Nat Biotechnol 34, 675–676 (2016). https://doi.org/10.1038/nbt0716-675

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0716-675

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation